Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Fallet

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Respiratory Medicine and Research|April 11, 2025
Management of non-small cell lung cancer after 2 years of immunotherapyCédric Mahiat, Jacques Cadranel, Constance Méteyé, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophagesThibault Vieira, Martine Antoine, Cécile Hamard, et al.
Frontiers in Oncology|July 14, 2023
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case ReportsLionel Michaux, Alexandre Perrier, Camille Mehlman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patientVincent Fallet, Anne-Marie Ruppert, Virginie Poulot, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 11, 2019
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancerJacques Cadranel, Anthony Canellas, Lise Matton, et al.
Bulletin Du Cancer|March 8, 2022
[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]Vincent Fallet, Pascal Rouby, Guido Ahle, et al.
Cardiovascular and Interventional Radiology|August 24, 2019
Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial ExperienceFrançois H Cornelis, Mohamed Ben Ammar, Maud Nouri-Neuville, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2014
Prospective screening for ALK: clinical features and outcome according to ALK statusVincent Fallet, Jacques Cadranel, Hélène Doubre, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Respiratory Medicine and Research|April 11, 2025
Management of non-small cell lung cancer after 2 years of immunotherapyCédric Mahiat, Jacques Cadranel, Constance Méteyé, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophagesThibault Vieira, Martine Antoine, Cécile Hamard, et al.
Frontiers in Oncology|July 14, 2023
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case ReportsLionel Michaux, Alexandre Perrier, Camille Mehlman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patientVincent Fallet, Anne-Marie Ruppert, Virginie Poulot, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 11, 2019
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancerJacques Cadranel, Anthony Canellas, Lise Matton, et al.
Bulletin Du Cancer|March 8, 2022
[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]Vincent Fallet, Pascal Rouby, Guido Ahle, et al.
Cardiovascular and Interventional Radiology|August 24, 2019
Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial ExperienceFrançois H Cornelis, Mohamed Ben Ammar, Maud Nouri-Neuville, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2014
Prospective screening for ALK: clinical features and outcome according to ALK statusVincent Fallet, Jacques Cadranel, Hélène Doubre, et al.
Pageof 6